GKL-006
Phase 2Biologic
GKL-006 is one of 15 biologic programs targeting Hepatocellular Carcinoma (HCC). It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Hepatocellular Carcinoma (HCC)
#DrugCompanyPhaseTrials
1Avastin
RochePhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Tecentriq
RochePhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Farxiga
AstraZenecaPhase 2
Beyfortus
BeiGenePhase 2
Zofran
NovartisPhase 2
Imfinzi
AstraZenecaPhase 2
Nitrostat
VViatris Specialty LLC
Phase 2
Actemra
CCelltrion
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GKL-006. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details